Scotiabank analyst Greg Harrison lowered the firm’s price target on Vera Therapeutics (VERA) to $55 from $60 and keeps an Outperform rating on the shares. The firm is updating its price targets on biotechnology stocks following Q1 results, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics: Strategic Advancements and Strong Financial Position Underpin Buy Rating
- Vera Therapeutics price target lowered to $26 from $34 at Wedbush
- Vera Therapeutics Advances Atacicept in Key Trials
- Vera Therapeutics: Strong Financials and Promising Clinical Developments Support Buy Rating
- Vera Therapeutics reports Q1 EPS (81c), consensus (78c)